Core Insights - Co-Diagnostics, Inc. is participating in the Global Health Exhibition 2025 in Riyadh, Saudi Arabia, showcasing its innovative molecular diagnostic technologies [1][3] - The company recently announced a Memorandum of Understanding (MOU) for a joint venture with a regional manufacturing and distribution company in Saudi Arabia, aimed at developing and commercializing its diagnostic products in the Middle East and North Africa [4][6] Company Participation - The executive leadership team, including CEO Dwight Egan and President Richard Abbott, will represent the company at the exhibition [2] - The exhibition is expected to attract over 160,000 healthcare professionals and numerous brands and investors from around the globe [3] Joint Venture Details - The anticipated joint venture will focus on the development, manufacture, and sale of Co-Diagnostics' intellectual property, including the Co-Dx PCR point-of-care platform [4] - The new platform and other infectious disease PCR products will be showcased at Booth H3.L17 during the exhibition [4][5] Company Overview - Co-Diagnostics, Inc. specializes in molecular diagnostics, developing technologies for detecting and analyzing nucleic acid molecules [6] - The company's proprietary technology is designed for specific tests related to its Co-Dx PCR platform, which is currently under regulatory review and not available for sale [5][6]

*The Co-Dx PCR platform (including the Co-Dx PCR Homeâ"¢, Co-Dx PCR Proâ"¢, mobile app, and all associated tests and software) is subject to review by the FDA and/or other regulatory bodies and is not available for sale. Accessibility StatementSkip Navigation New device has the potential to help empower decentralized PCR testing in nearly 30,000 primary health centers across India, advancing efforts to improve availability of life-saving TB diagnostics SALT LAKE CITY, Oct. 16, 2025 /PRNewswire/ -- Co-Diagno ...

, /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today its participation in the upcoming 2025 Maxim Growth Summit, taking place October 22-23 at The Hard Rock Hotel NYC. The prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries. Keynote speakers ...

Summary of Co-Diagnostics Conference Call Company Overview - Co-Diagnostics, Inc. is a public company established in 2013, headquartered in Salt Lake City, Utah, with approximately 120 employees and a significant joint venture in India [2][3] - The company went public on NASDAQ in 2017 under the ticker symbol CODX [2] Core Business and Vision - The primary vision is to democratize affordable real-time molecular diagnostics across various diseases, aiming to improve healthcare delivery through accessibility, affordability, and accuracy [3] - During the pandemic, Co-Diagnostics sold approximately 35 million tests globally across more than 50 countries [3] Product Offerings - The main product is the CODX PCR platform, which is currently under FDA regulatory review and not for sale [2] - The CoPrimers technology allows for multiplex testing, enabling the detection of multiple diseases from a single sample [5][6] - Current infectious disease product offerings include tests for HPV, flu A/B/COVID-19/RSV, and mosquito vector control tests for diseases like Zika and dengue [9][10] Technology and User Experience - The CODX PCR Pro is a compact, affordable real-time PCR diagnostic device that connects to a smartphone for user-friendly operation and cloud-based data aggregation [10][11] - The testing process takes approximately 30 minutes from sample collection to result [13] - High user ratings indicate a positive experience with the smartphone-guided testing process [7] Market Opportunities - The addressable market in the U.S. includes over 14,000 urgent care facilities, nearly 850,000 physicians, and more than 60,000 pharmacies [14][15] - The home testing market is also targeted, allowing patients to conduct tests without visiting healthcare facilities [17] Joint Venture in India - Co-Diagnostics has a joint venture in India established in 2017, with 15 tests authorized by the CDSCO, including tests for hepatitis, malaria, and COVID-19 [19] - A new facility in India focuses on manufacturing oligonucleotides, enhancing local production capabilities [20] - The company aims to replace outdated microscopy technology with its molecular testing solutions in India, targeting a significant market opportunity [22][23] Regulatory Strategy - The company plans to pursue FDA clearance for its multiplex tests, including influenza A, B, and COVID-19/RSV [24] - In India, the focus will be on tuberculosis and HPV tests, with plans for regulatory submissions in South Africa and Saudi Arabia [25] Future Aspirations - Co-Diagnostics anticipates expanding its test menu to include multiplex sexually transmitted infections and tests for pets and livestock [26] Conclusion - The conference highlighted significant growth opportunities for Co-Diagnostics, driven by innovative technology, strategic market positioning, and a commitment to improving healthcare accessibility [27]

SALT LAKE CITY, Sept. 30, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be participating in a webcast presentation and hosting one-on-one meetings with institutional investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025. Company Webcast The Company presentation w ...

Core Viewpoint - Top Wall Street analysts have revised their outlook on several prominent companies, indicating potential shifts in investment sentiment and opportunities in the market [1] Group 1: Analyst Ratings Changes - Analysts have made notable upgrades and downgrades on various stocks, reflecting changing perspectives on their future performance [1] - The article suggests that investors should consider the insights from analysts when evaluating stocks like TSLA [1]

Group 1 - Co-Diagnostics (CODX) has signed a strategic Memorandum of Understanding (MOU) with a regional manufacturing and distribution company in Saudi Arabia to explore a joint venture [1] - The joint venture will be licensed to develop, manufacture, and sell Co-Dx intellectual property across the Middle East and North Africa, including the upcoming Co-Dx PCR point-of-care platform [1] - The Saudi partner will provide local operational support, access to infrastructure, personnel, regulatory expertise, and other critical resources for the joint venture's objectives [1]

Core Insights - Co-Diagnostics Inc. experienced a significant stock price drop of 28.26% to $0.46 in pre-market trading, reversing the previous day's 80.76% surge to $0.64 [1][3] - The company announced a Memorandum of Understanding with a Saudi Arabian partner to explore a joint venture for developing and distributing its Co-Dx™ PCR platform technology in the Middle East and North Africa [2][4] Company Developments - The proposed joint venture will allow the Saudi partner to license Co-Diagnostics' intellectual property, including the upcoming Co-Dx™ PCR point-of-care platform, for the MENA markets [4] - CEO Dwight Egan highlighted the alignment of this initiative with Saudi Arabia's Vision 2030 [5] - The Co-Dx PCR platform is currently under FDA regulatory review and is not yet commercially available [6] Market Context - The stock has seen a decline of 36% from its peak of $1 on January 6, closing at $0.64 recently, despite a surge in trading volume from 1.8 million to 243 million shares [7] - Co-Diagnostics has a market capitalization of $24.85 million and trades within a 52-week range of $0.23 to $1.40 [7] - The company is experiencing long-term consolidation with medium and short-term upward movement according to Benzinga's Edge Stock Rankings [8]

Accessibility StatementSkip Navigation As of July, there have been nearly 250,000 cases and 90 deaths from CHIKV worldwide, primarily concentrated in South America, but also found in countries across Africa, Asia and Europe. An estimated 5.6 billion people currently live in at-risk areas across 119 countries as warming trends contribute to expanded regions for the mosquitoes that can carry CHIKV. Chikungunya imposes a significant economic burden, especially in low- and middle-income countries. Long- term co ...

Core Insights - Co-Diagnostics, Inc. has been recognized at the Utah Business 2025 Innovation Awards Summit for its Co-Dx PCR platform in the Healthcare and Life Sciences category [1][2] - The award was accepted by CEO Dwight Egan, highlighting the company's innovative approach to molecular diagnostics [2][3] - The Co-Dx PCR platform aims to improve access to high-quality PCR diagnostics globally, with commercialization expected next year [3] Company Overview - Co-Diagnostics, Inc. is a molecular diagnostics company based in Utah, specializing in the development, manufacturing, and marketing of advanced diagnostic technologies [4] - The company's proprietary technology is utilized for tests designed to detect and analyze nucleic acid molecules (DNA or RNA) [4] - Co-Diagnostics also focuses on creating specific tests for its Co-Dx PCR at-home and point-of-care platform, as well as identifying genetic markers for various applications beyond infectious diseases [4]